PandemieGrippaleV1, PascalFrancis, Curation, bibRecord, 001D05

Intranasal vaccination with a replication-deficient influenza virus induces heterosubtypic neutralising mucosal IgA antibodies in humans

Identifieur interne : 001D05 ( PascalFrancis/Curation ); précédent : 001D04; suivant : 001D06

Intranasal vaccination with a replication-deficient influenza virus induces heterosubtypic neutralising mucosal IgA antibodies in humans

Auteurs : A. Morokutti [Autriche] ; T. Muster [Autriche] ; B. Ferko [Autriche]

Source :

Vaccine [ 0264-410X ] ; 2014.

RBID : Pascal:14-0118326

Descripteurs français

Pascal (Inist)
- Virus grippal A, Homme, Influenzavirus, Voie intranasale, Vaccination, Réplication, Anticorps neutralisant, Immunité locale, IgA, Immunisation, Vaccin.
Wicri :
- topic : Homme, Vaccination, Vaccin.

English descriptors

KwdEn :
- Human, IgA, Immunization, Influenza A virus, Influenzavirus, Intranasal administration, Local immunity, Neutralizing antibody, Replication, Vaccination, Vaccine.

Abstract

We investigated the cross-neutralising potential of serum and nasal wash samples from volunteers who were intranasally immunised once with a monovalent replication-deficient deINS1-H1N1 influenza virus vaccine (7.7 log₁₀ TCID₅₀/volunteer). Eight out of twelve (8/12) vaccinees responded to vaccination with a significant increase of antibody levels in serum IgG ELISA, mucosal IgA ELISA, MNA or HAI. Four responders showed deINS1-specific ELISA IgA increases and revealed excellent homosubtypic neutralising activity in serum and mucosal washings (4/4). However, 0/4 of the sera but 3/4 of the nasal washings neutralised also heterosubtypic H3N2 and H5N1 influenza viruses. Depletion experiments proved that IgA but not IgG is responsible for the cross-neutralising activity of the nasal wash sample. Our findings indicate that the induction of virus-neutralising IgA may represent a valuable correlate of cross-protection of intranasal influenza vaccines and that the deINS1 concept constitutes a promising approach to protect humans from seasonal and pandemic influenza threats.

A01	`01`	`1`		`@0 0264-410X`
A02	`01`			`@0 VACCDE`
A03		`1`		`@0 Vaccine`
A05				`@2 32`
A06				`@2 17`
A08	`01`	`1`	`ENG`	`@1 Intranasal vaccination with a replication-deficient influenza virus induces heterosubtypic neutralising mucosal IgA antibodies in humans`
A11	`01`	`1`		`@1 MOROKUTTI (A.)`
A11	`02`	`1`		`@1 MUSTER (T.)`
A11	`03`	`1`		`@1 FERKO (B.)`
A14	`01`			`@1 AVIR Green Hills Biotechnology AG @2 Vienna @3 AUT @Z 1 aut. @Z 2 aut. @Z 3 aut.`
A14	`02`			`@1 University of Natural Resources and Life Sciences @2 Vienna @3 AUT @Z 1 aut.`
A20				`@1 1897-1900`
A21				`@1 2014`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 20289 @5 354000503236260010`
A44				`@0 0000 @1 © 2014 INIST-CNRS. All rights reserved.`
A45				`@0 22 ref.`
A47	`01`	`1`		`@0 14-0118326`
A60				`@1 P @3 CC`
A61				`@0 A`
A64	`01`	`1`		`@0 Vaccine`
A66	`01`			`@0 GBR`
C01	`01`		`ENG`	@0 We investigated the cross-neutralising potential of serum and nasal wash samples from volunteers who were intranasally immunised once with a monovalent replication-deficient deINS1-H1N1 influenza virus vaccine (7.7 log₁₀ TCID₅₀/volunteer). Eight out of twelve (8/12) vaccinees responded to vaccination with a significant increase of antibody levels in serum IgG ELISA, mucosal IgA ELISA, MNA or HAI. Four responders showed deINS1-specific ELISA IgA increases and revealed excellent homosubtypic neutralising activity in serum and mucosal washings (4/4). However, 0/4 of the sera but 3/4 of the nasal washings neutralised also heterosubtypic H3N2 and H5N1 influenza viruses. Depletion experiments proved that IgA but not IgG is responsible for the cross-neutralising activity of the nasal wash sample. Our findings indicate that the induction of virus-neutralising IgA may represent a valuable correlate of cross-protection of intranasal influenza vaccines and that the deINS1 concept constitutes a promising approach to protect humans from seasonal and pandemic influenza threats.
C02	`01`	`X`		`@0 002A05F04`
C02	`02`	`X`		`@0 002A05C10`
C03	`01`	`X`	`FRE`	`@0 Virus grippal A @2 NW @5 01`
C03	`01`	`X`	`ENG`	`@0 Influenza A virus @2 NW @5 01`
C03	`01`	`X`	`SPA`	`@0 Influenza A virus @2 NW @5 01`
C03	`02`	`X`	`FRE`	`@0 Homme @5 02`
C03	`02`	`X`	`ENG`	`@0 Human @5 02`
C03	`02`	`X`	`SPA`	`@0 Hombre @5 02`
C03	`03`	`X`	`FRE`	`@0 Influenzavirus @2 NW @5 03`
C03	`03`	`X`	`ENG`	`@0 Influenzavirus @2 NW @5 03`
C03	`03`	`X`	`SPA`	`@0 Influenzavirus @2 NW @5 03`
C03	`04`	`X`	`FRE`	`@0 Voie intranasale @5 05`
C03	`04`	`X`	`ENG`	`@0 Intranasal administration @5 05`
C03	`04`	`X`	`SPA`	`@0 Vía intranasal @5 05`
C03	`05`	`X`	`FRE`	`@0 Vaccination @5 06`
C03	`05`	`X`	`ENG`	`@0 Vaccination @5 06`
C03	`05`	`X`	`SPA`	`@0 Vacunación @5 06`
C03	`06`	`X`	`FRE`	`@0 Réplication @5 07`
C03	`06`	`X`	`ENG`	`@0 Replication @5 07`
C03	`06`	`X`	`SPA`	`@0 Replicación @5 07`
C03	`07`	`X`	`FRE`	`@0 Anticorps neutralisant @5 08`
C03	`07`	`X`	`ENG`	`@0 Neutralizing antibody @5 08`
C03	`07`	`X`	`SPA`	`@0 anticuerpo neutralizante @5 08`
C03	`08`	`X`	`FRE`	`@0 Immunité locale @5 09`
C03	`08`	`X`	`ENG`	`@0 Local immunity @5 09`
C03	`08`	`X`	`SPA`	`@0 Inmunidad local @5 09`
C03	`09`	`X`	`FRE`	`@0 IgA @5 10`
C03	`09`	`X`	`ENG`	`@0 IgA @5 10`
C03	`09`	`X`	`SPA`	`@0 IgA @5 10`
C03	`10`	`X`	`FRE`	`@0 Immunisation @5 11`
C03	`10`	`X`	`ENG`	`@0 Immunization @5 11`
C03	`10`	`X`	`SPA`	`@0 Inmunización @5 11`
C03	`11`	`X`	`FRE`	`@0 Vaccin @5 12`
C03	`11`	`X`	`ENG`	`@0 Vaccine @5 12`
C03	`11`	`X`	`SPA`	`@0 Vacuna @5 12`
C07	`01`	`X`	`FRE`	`@0 Influenzavirus A @2 NW`
C07	`01`	`X`	`ENG`	`@0 Influenzavirus A @2 NW`
C07	`01`	`X`	`SPA`	`@0 Influenzavirus A @2 NW`
C07	`02`	`X`	`FRE`	`@0 Orthomyxoviridae @2 NW`
C07	`02`	`X`	`ENG`	`@0 Orthomyxoviridae @2 NW`
C07	`02`	`X`	`SPA`	`@0 Orthomyxoviridae @2 NW`
C07	`03`	`X`	`FRE`	`@0 Virus @2 NW`
C07	`03`	`X`	`ENG`	`@0 Virus @2 NW`
C07	`03`	`X`	`SPA`	`@0 Virus @2 NW`
N21				`@1 153`
N44	`01`			`@1 OTO`
N82				`@1 OTO`

Links toward previous steps (curation, corpus...)

to stream PascalFrancis, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000114

Links to Exploration step

Pascal:14-0118326

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Intranasal vaccination with a replication-deficient influenza virus induces heterosubtypic neutralising mucosal IgA antibodies in humans</title>
<author><name sortKey="Morokutti, A" sort="Morokutti, A" uniqKey="Morokutti A" first="A." last="Morokutti">A. Morokutti</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>AVIR Green Hills Biotechnology AG</s1>
<s2>Vienna</s2>
<s3>AUT</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>Autriche</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>University of Natural Resources and Life Sciences</s1>
<s2>Vienna</s2>
<s3>AUT</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
<country>Autriche</country>
</affiliation>
</author>
<author><name sortKey="Muster, T" sort="Muster, T" uniqKey="Muster T" first="T." last="Muster">T. Muster</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>AVIR Green Hills Biotechnology AG</s1>
<s2>Vienna</s2>
<s3>AUT</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>Autriche</country>
</affiliation>
</author>
<author><name sortKey="Ferko, B" sort="Ferko, B" uniqKey="Ferko B" first="B." last="Ferko">B. Ferko</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>AVIR Green Hills Biotechnology AG</s1>
<s2>Vienna</s2>
<s3>AUT</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>Autriche</country>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">14-0118326</idno>
<date when="2014">2014</date>
<idno type="stanalyst">PASCAL 14-0118326 INIST</idno>
<idno type="RBID">Pascal:14-0118326</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000114</idno>
<idno type="wicri:Area/PascalFrancis/Curation">001D05</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Intranasal vaccination with a replication-deficient influenza virus induces heterosubtypic neutralising mucosal IgA antibodies in humans</title>
<author><name sortKey="Morokutti, A" sort="Morokutti, A" uniqKey="Morokutti A" first="A." last="Morokutti">A. Morokutti</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>AVIR Green Hills Biotechnology AG</s1>
<s2>Vienna</s2>
<s3>AUT</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>Autriche</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>University of Natural Resources and Life Sciences</s1>
<s2>Vienna</s2>
<s3>AUT</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
<country>Autriche</country>
</affiliation>
</author>
<author><name sortKey="Muster, T" sort="Muster, T" uniqKey="Muster T" first="T." last="Muster">T. Muster</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>AVIR Green Hills Biotechnology AG</s1>
<s2>Vienna</s2>
<s3>AUT</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>Autriche</country>
</affiliation>
</author>
<author><name sortKey="Ferko, B" sort="Ferko, B" uniqKey="Ferko B" first="B." last="Ferko">B. Ferko</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>AVIR Green Hills Biotechnology AG</s1>
<s2>Vienna</s2>
<s3>AUT</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>Autriche</country>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Vaccine</title>
<title level="j" type="abbreviated">Vaccine</title>
<idno type="ISSN">0264-410X</idno>
<imprint><date when="2014">2014</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Vaccine</title>
<title level="j" type="abbreviated">Vaccine</title>
<idno type="ISSN">0264-410X</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Human</term>
<term>IgA</term>
<term>Immunization</term>
<term>Influenza A virus</term>
<term>Influenzavirus</term>
<term>Intranasal administration</term>
<term>Local immunity</term>
<term>Neutralizing antibody</term>
<term>Replication</term>
<term>Vaccination</term>
<term>Vaccine</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Virus grippal A</term>
<term>Homme</term>
<term>Influenzavirus</term>
<term>Voie intranasale</term>
<term>Vaccination</term>
<term>Réplication</term>
<term>Anticorps neutralisant</term>
<term>Immunité locale</term>
<term>IgA</term>
<term>Immunisation</term>
<term>Vaccin</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Homme</term>
<term>Vaccination</term>
<term>Vaccin</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">We investigated the cross-neutralising potential of serum and nasal wash samples from volunteers who were intranasally immunised once with a monovalent replication-deficient deINS1-H1N1 influenza virus vaccine (7.7 log<sub>10</sub>
 TCID<sub>50</sub>
/volunteer). Eight out of twelve (8/12) vaccinees responded to vaccination with a significant increase of antibody levels in serum IgG ELISA, mucosal IgA ELISA, MNA or HAI. Four responders showed deINS1-specific ELISA IgA increases and revealed excellent homosubtypic neutralising activity in serum and mucosal washings (4/4). However, 0/4 of the sera but 3/4 of the nasal washings neutralised also heterosubtypic H3N2 and H5N1 influenza viruses. Depletion experiments proved that IgA but not IgG is responsible for the cross-neutralising activity of the nasal wash sample. Our findings indicate that the induction of virus-neutralising IgA may represent a valuable correlate of cross-protection of intranasal influenza vaccines and that the deINS1 concept constitutes a promising approach to protect humans from seasonal and pandemic influenza threats.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0264-410X</s0>
</fA01>
<fA02 i1="01"><s0>VACCDE</s0>
</fA02>
<fA03 i2="1"><s0>Vaccine</s0>
</fA03>
<fA05><s2>32</s2>
</fA05>
<fA06><s2>17</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Intranasal vaccination with a replication-deficient influenza virus induces heterosubtypic neutralising mucosal IgA antibodies in humans</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>MOROKUTTI (A.)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>MUSTER (T.)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>FERKO (B.)</s1>
</fA11>
<fA14 i1="01"><s1>AVIR Green Hills Biotechnology AG</s1>
<s2>Vienna</s2>
<s3>AUT</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>University of Natural Resources and Life Sciences</s1>
<s2>Vienna</s2>
<s3>AUT</s3>
<sZ>1 aut.</sZ>
</fA14>
<fA20><s1>1897-1900</s1>
</fA20>
<fA21><s1>2014</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>20289</s2>
<s5>354000503236260010</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2014 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>22 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>14-0118326</s0>
</fA47>
<fA60><s1>P</s1>
<s3>CC</s3>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Vaccine</s0>
</fA64>
<fA66 i1="01"><s0>GBR</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>We investigated the cross-neutralising potential of serum and nasal wash samples from volunteers who were intranasally immunised once with a monovalent replication-deficient deINS1-H1N1 influenza virus vaccine (7.7 log<sub>10</sub>
 TCID<sub>50</sub>
/volunteer). Eight out of twelve (8/12) vaccinees responded to vaccination with a significant increase of antibody levels in serum IgG ELISA, mucosal IgA ELISA, MNA or HAI. Four responders showed deINS1-specific ELISA IgA increases and revealed excellent homosubtypic neutralising activity in serum and mucosal washings (4/4). However, 0/4 of the sera but 3/4 of the nasal washings neutralised also heterosubtypic H3N2 and H5N1 influenza viruses. Depletion experiments proved that IgA but not IgG is responsible for the cross-neutralising activity of the nasal wash sample. Our findings indicate that the induction of virus-neutralising IgA may represent a valuable correlate of cross-protection of intranasal influenza vaccines and that the deINS1 concept constitutes a promising approach to protect humans from seasonal and pandemic influenza threats.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002A05F04</s0>
</fC02>
<fC02 i1="02" i2="X"><s0>002A05C10</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Virus grippal A</s0>
<s2>NW</s2>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Influenza A virus</s0>
<s2>NW</s2>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Influenza A virus</s0>
<s2>NW</s2>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Homme</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Human</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Hombre</s0>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Influenzavirus</s0>
<s2>NW</s2>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Influenzavirus</s0>
<s2>NW</s2>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Influenzavirus</s0>
<s2>NW</s2>
<s5>03</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Voie intranasale</s0>
<s5>05</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Intranasal administration</s0>
<s5>05</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Vía intranasal</s0>
<s5>05</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Vaccination</s0>
<s5>06</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Vaccination</s0>
<s5>06</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Vacunación</s0>
<s5>06</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Réplication</s0>
<s5>07</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Replication</s0>
<s5>07</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Replicación</s0>
<s5>07</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Anticorps neutralisant</s0>
<s5>08</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Neutralizing antibody</s0>
<s5>08</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>anticuerpo neutralizante</s0>
<s5>08</s5>
</fC03>
<fC03 i1="08" i2="X" l="FRE"><s0>Immunité locale</s0>
<s5>09</s5>
</fC03>
<fC03 i1="08" i2="X" l="ENG"><s0>Local immunity</s0>
<s5>09</s5>
</fC03>
<fC03 i1="08" i2="X" l="SPA"><s0>Inmunidad local</s0>
<s5>09</s5>
</fC03>
<fC03 i1="09" i2="X" l="FRE"><s0>IgA</s0>
<s5>10</s5>
</fC03>
<fC03 i1="09" i2="X" l="ENG"><s0>IgA</s0>
<s5>10</s5>
</fC03>
<fC03 i1="09" i2="X" l="SPA"><s0>IgA</s0>
<s5>10</s5>
</fC03>
<fC03 i1="10" i2="X" l="FRE"><s0>Immunisation</s0>
<s5>11</s5>
</fC03>
<fC03 i1="10" i2="X" l="ENG"><s0>Immunization</s0>
<s5>11</s5>
</fC03>
<fC03 i1="10" i2="X" l="SPA"><s0>Inmunización</s0>
<s5>11</s5>
</fC03>
<fC03 i1="11" i2="X" l="FRE"><s0>Vaccin</s0>
<s5>12</s5>
</fC03>
<fC03 i1="11" i2="X" l="ENG"><s0>Vaccine</s0>
<s5>12</s5>
</fC03>
<fC03 i1="11" i2="X" l="SPA"><s0>Vacuna</s0>
<s5>12</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Influenzavirus A</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Influenzavirus A</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Influenzavirus A</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Orthomyxoviridae</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Orthomyxoviridae</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Orthomyxoviridae</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Virus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Virus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Virus</s0>
<s2>NW</s2>
</fC07>
<fN21><s1>153</s1>
</fN21>
<fN44 i1="01"><s1>OTO</s1>
</fN44>
<fN82><s1>OTO</s1>
</fN82>
</pA>
</standard>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/PandemieGrippaleV1/Data/PascalFrancis/Curation

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001D05 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Curation/biblio.hfd -nk 001D05 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    PandemieGrippaleV1
   |flux=    PascalFrancis
   |étape=   Curation
   |type=    RBID
   |clé=     Pascal:14-0118326
   |texte=   Intranasal vaccination with a replication-deficient influenza virus induces heterosubtypic neutralising mucosal IgA antibodies in humans
}}

This area was generated with Dilib version V0.6.34.
Data generation: Wed Jun 10 11:04:28 2020. Site generation: Sun Mar 28 09:10:28 2021

	Serveur d'exploration sur les pandémies grippales
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration sur les pandémies grippales

Intranasal vaccination with a replication-deficient influenza virus induces heterosubtypic neutralising mucosal IgA antibodies in humans

Intranasal vaccination with a replication-deficient influenza virus induces heterosubtypic neutralising mucosal IgA antibodies in humans

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri